ClinicalTrials.gg
CompletedNCT06507839Updated May 13, 2025

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

A Phase 1 interventional study of THRV-1268 and Placebo in Atrial Fibrillation, sponsored by Thryv Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Thryv Therapeutics, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.

Enrollment
219th of 261
56 · median 282
Started
2024
with 19 others
Phase 1
4 of 318
none open now
Registered
296th of 318
by date

Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 219th largest by enrollment of the 261 interventional ones that give a count, is one of 20 that started in 2024, is one of 4 in phase 1, and was the 296th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Atrial Fibrillation with a site in Canada, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • THRV-1268
  • Atrial Fibrillation
  • Serum glucocorticoid regulated kinase-1
  • SGK-1 inhibitor
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Provision of signed and dated Form (ICF). 2.Stated willingness to comply with all study procedures and availability for the duration of the study.

3.Healthy adult male or female subjects. 4.If female, meets one of the following criteria:

  • Women of who agrees to use any of the acceptable methods:

    1. Abstinence from heterosexual intercourse from Screening through at least 30 days from last study dose.
    2. One of the following highly-effective contraception methods:

      1. systemic contraceptives (combined birth control pills, injectable/implant/ insertable hormonal birth control products, or transdermal patch) used from at least 28 days prior to Screening through to at least 30 days from last study dose
      2. intrauterine device (with or without hormones) used from at least 28 days prior to Screening through to at least 30 days from last study dose
      3. male partner vasectomized at least 6 months prior to Screening visit
    3. One of the following double-barrier contraception methods used from Screening through at least 30 days from last study dose

      1. Male condom used simultaneously with diaphragm plus spermicide
      2. Male condom used simultaneously with cervical cap plus spermicide Or
  • Physiological status, defined as the absence of menses for at least 12 months following cessation of all exogenous hormonal treatments (without an alternative medical condition) at Screening and prior to the first study drug administration and have follicle stimulating hormone (FSH) levels ≥ 40 mIU/mL at Screening (If subject is postmenopausal and has an FSH of \< 40 mIU/mL, but meets all other criteria in (1) or (2) above as well as all the other inclusion criteria, screening estradiol serum level must be equal to or below 150 pmol/L. In the case of hysterectomy, if FSH and estradiol do not meet the criteria, eligibility for study participation will be based on medical judgment.).

Or

  • Surgically sterile, defined as those who have had hysterectomy, bilateral oophorectomy and/or bilateral salpingectomy, or bilateral tubal ligation.

    5.Men who are biologically capable of fathering children must agree and commit to use an adequate form of contraception (see female criteria 3) for the duration of the treatment period and for no less than 90 days after the last study dose. A male subject is considered capable of fathering children even if his sexual partner is sterile or using contraceptives.

    6.Men who are biologically capable of fathering children must also agree to refrain from sperm donation for the duration of the treatment period and for at least 90 days after the last study dose.

    7.Aged at least 18 years but not older than 60 years (inclusive). 8. (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively. 9.Non- or ex-smoker (An ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration).

    10.Have no diseases captured in the medical history or evidence of clinically significant findings in the physical examination (including vital signs) and/or , as determined by an Investigator.

Exclusion criteria

Exclusion Criteria:

  1. gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition, which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  2. Clinically significant abnormal findings on the physical examination or medical history during Screening as deemed by the Investigator.
  3. Female who is lactating.
  4. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration.
  5. Male subjects with a history of oligospermia or azoospermia or any other disorder of the reproductive system.
  6. Male subjects who are undergoing treatment or evaluation for infertility.
  7. The average of 3 measurements performed approximately 5 min apart: Screening or baseline (Day -1) diastolic BP \<50 mmHg or >95; systolic BP \<100 mmHg or >145 mmHg; or HR ≤ 50 beats per minute (bpm) using a validated digital BP device. These can be repeated in triplicate once after an additional quiet resting period.
  8. Orthostatic BP performed after sitting quietly for at least 4 minutes and then standing for 2 minutes with a duplicate set performed after at least 3 minutes of sitting, with a reduction in systolic BP >20 mmHg, a reduction in diastolic BP >10 mmHg, or an increase in HR >20 bpm using a validated digital BP device.
  9. Estimated \< 80 mL/min at Screening.
  10. History of significant to THRV-1268, kinase inhibitors or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
  11. Screening 12-lead demonstrating at least one of the following: PR >220 ms; QRS >110 ms, or >440 ms; atrioventricular block; branch bundle block, significant ST-T wave abnormalities or flat T waves that could interfere with QT analysis. Heart rate ≤50 bpm or >100 bpm.
  12. History or evidence of any of the following: myocardial infarction; cardiac valvulopathy; cardiac surgery revascularization (coronary artery bypass grafting or percutaneous, transluminal coronary angioplasty); unstable angina; cerebrovascular accident, stroke, or ; pacemaker; AF, flutter, or nonsustained or sustained ventricular tachycardia; orthostatic hypotension or orthostatic dizziness or lightheadedness, pulmonary arterial hypertension; sick sinus syndrome, second- or third-degree atrioventricular block; uncontrolled hypertension; congestive heart failure; personal or family history of sudden death or long QT syndrome; unexplained syncope or syncope within the last 3 years regardless of etiology.
  13. Immunization with a Coronavirus Disease (COVID-19) vaccine in the 14 days prior to the first study drug administration.
  14. Scheduled immunization with a COVID-19 vaccine during the study that, in the opinion of an Investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason.
  15. Use of in the 28 days or 5 half-lives (whichever is longer) prior to the first study drug administration.
  16. Major surgery with prolonged immobilization in the 28 days prior to the first study drug administration.
  17. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).
  18. Any clinically significant illness in the 28 days prior to the first study drug administration.
  19. Use of any over-the-counter or nutritional supplements in the last 7 days prior to the first study drug administration and during the study, that in the opinion of an Investigator would put into question the status of the subject as healthy.
  20. Use of any prescription drugs (except for hormonal or hormone replacement therapy) in the 28 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the subject as healthy.
  21. Use of St. John's wort in the 28 days prior to the first study drug administration.
  22. Any history of tuberculosis.
  23. value below the lower limit of the reference laboratory at Screening, unless deemed non-significant by the Investigator.
  24. Abnormal screening values in potassium, magnesium, (ALT), aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total , and direct bilirubin values, unless deemed non-significant by the Investigator.
  25. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration.
  26. Positive screening results to Ag/Ab combo, surface antigen or virus antibody tests.
  27. Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
  28. History of prior administration of THRV-1268 or inclusion in a previous cohort for this clinical study.
  29. Intake of an IP or participation in a clinical trial in the 28 days or 5 half-lives (whichever is longer) prior to the first study drug administration.
  30. Unable or unwilling to adhere to the lifestyle and dietary requirements described in Section 4.4.
  31. Special diet or substantial changes in eating habits in the last 1 month before Screening.
  32. Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration.
  33. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD) THRV-1268

    5 dosing cohorts will receive a single oral dose of THRV-1268. The highest dose of THRV-1268 to be administered is 500 mg.

    Drug: THRV-1268

  • Experimental
    Food Effect THRV-1268

    food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.

    Drug: THRV-1268

  • Experimental
    Multiple Ascending Dose (MAD) THRV-1268

    3 dosing cohorts will receive THRV-1268 in the morning on Day 1 to Day 7.

    Drug: THRV-1268

  • Placebo comparator
    Single Ascending Dose (SAD) Placebo

    5 dosing cohorts will receive a single oral dose of placebo.

    Other: Placebo

  • Placebo comparator
    Food Effect Placebo

    Food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.

    Other: Placebo

  • Placebo comparator
    Multiple Ascending Dose (MAD) Placebo

    3 dosing cohorts will receive placebo in the morning from Day 1 to Day 7.

    Other: Placebo

Interventions

  • THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

  • OtherPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability: Number of Participants with Adverse Events

    Number of Participants with Adverse Events

    Time frame: SAD: Day 7; Food Effect: Day 15; MAD: Day 16

Secondary outcomes

  1. Pharmacokinetic LQT-1268 AUC0-t

    Area under the concentration-time curve (AUC) from time 0 to the time of the last

    Time frame: SAD: Day 1; Food Effect: Serially on Day 1 and Day 8; MAD: Serially on Day 1 and 7

  2. Pharmacokinetic LQT-1268 Cmax

    Maximum observed plasma drug concentration

    Time frame: SAD: Day 1; Food Effect: Serially on Day 1 and Day 8; MAD: Serially on Day 1 and 7

  3. Pharmacokinetic LQT-1268 Tmax

    Time to maximum observed plasma drug concentration

    Time frame: SAD: Day 1; Food Effect: Serially on Day 1 and Day 8; MAD: Serially on Day 1 and 7

  4. Pharmacokinetic LQT-1268 t1/2

    Time to maximum observed plasma drug concentration

    Time frame: SAD: Day 1; Food Effect: Serially on Day 1 and Day 8; MAD: Serially on Day 1 and 7

  5. Urine Pharmacokinetics of LQT-1268: Ae

    Amount of the administered dose recovered over the entire 24-hour interval

    Time frame: SAD: Day 1; MAD: Serially on Day 1 and 7

  6. Urine Pharmacokinetics of LQT-1268: Fe

    Percentage of the administered dose recovered over the entire 24-hour interval

    Time frame: SAD: Day 1; MAD: Serially on Day 1 and 7

  7. Urine Pharmacokinetics of LQT-1268: Ae0-t

    Amount excreted unchanged in urine over a given time interval

    Time frame: SAD: Day 1; MAD: Serially on Day 1 and 7

  8. Plasma Pharmacokinetics of LQT-1268: Ctrough

    Concentration of drug in the blood immediately before the next dose is administered

    Time frame: MAD: Days 3-6

  9. Plasma Pharmacokinetics of LQT-1268: Rac(AUC)

    Drug accumulation ratio

    Time frame: MAD: Day 7

  10. Plasma Pharmacokinetics of LQT-1268: Rac(Cmax)

    Drug accumulation ratio

    Time frame: MAD: Day 7

07

Study locations

1 site
  • Altasciences
    Montreal, Quebec H3P 3P1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Nov 2024, 5 months.

Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 18, 2024
StartActual
May 15, 2024
Primary completionActual
Nov 1, 2024
CompletionActual
Nov 1, 2024
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06507839
Lead sponsor
Thryv Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
May 15, 2024
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
May 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THRV-1268

Start the discussion